UNLABELLED: The associations between diabetes, smoking, obesity, and intrahepatic cholangiocarcinoma (ICC) risk remain inconclusive. Metformin is purportedly associated with a reduced risk for various cancers. This case-control study evaluated risk factors for ICC and explored the effects of metformin on ICC risk in a clinic/hospital-based cohort. ICC patients observed at the Mayo Clinic (Rochester, MN) between January 2000 and May 2010 were identified. Age, sex, ethnicity, and residential area-matched controls were selected from among Mayo Clinic Biobank participants. The associations between potential factors and ICC risk were determined. Six hundred and twelve cases and 594 controls were identified. Factors associated with increased ICC risk included biliary tract diseases (adjusted odds ratio [AOR]: 81.8; 95% confidence interval [CI]: 11.2-598.8; P < 0.001), cirrhosis (AOR, 8.0; 95% CI: 1.8-36.5; P = 0.007), diabetes (AOR, 3.6; 95% CI: 2.3-5.5; P < 0.001), and smoking (AOR, 1.6; 95% CI: 1.3-2.1; P < 0.001). Compared to diabetic patients not treated with metformin, the odds ratio (OR) for ICC for diabetic patients treated with metformin was significantly decreased (OR, 0.4; 95% CI: 0.2-0.9; P = 0.04). Obesity and metabolic syndrome were not associated with ICC. CONCLUSION: This study confirmed diabetes and smoking as independent risk factors for ICC. A novel finding was that treatment with metformin was significantly associated with a 60% reduction in ICC risk in diabetic patients.
UNLABELLED: The associations between diabetes, smoking, obesity, and intrahepatic cholangiocarcinoma (ICC) risk remain inconclusive. Metformin is purportedly associated with a reduced risk for various cancers. This case-control study evaluated risk factors for ICC and explored the effects of metformin on ICC risk in a clinic/hospital-based cohort. ICC patients observed at the Mayo Clinic (Rochester, MN) between January 2000 and May 2010 were identified. Age, sex, ethnicity, and residential area-matched controls were selected from among Mayo Clinic Biobank participants. The associations between potential factors and ICC risk were determined. Six hundred and twelve cases and 594 controls were identified. Factors associated with increased ICC risk included biliary tract diseases (adjusted odds ratio [AOR]: 81.8; 95% confidence interval [CI]: 11.2-598.8; P < 0.001), cirrhosis (AOR, 8.0; 95% CI: 1.8-36.5; P = 0.007), diabetes (AOR, 3.6; 95% CI: 2.3-5.5; P < 0.001), and smoking (AOR, 1.6; 95% CI: 1.3-2.1; P < 0.001). Compared to diabeticpatients not treated with metformin, the odds ratio (OR) for ICC for diabeticpatients treated with metformin was significantly decreased (OR, 0.4; 95% CI: 0.2-0.9; P = 0.04). Obesity and metabolic syndrome were not associated with ICC. CONCLUSION: This study confirmed diabetes and smoking as independent risk factors for ICC. A novel finding was that treatment with metformin was significantly associated with a 60% reduction in ICC risk in diabeticpatients.
Authors: F Donato; U Gelatti; A Tagger; M Favret; M L Ribero; F Callea; C Martelli; A Savio; P Trevisi; G Nardi Journal: Cancer Causes Control Date: 2001-12 Impact factor: 2.506
Authors: Yasser H Shaib; Hashem B El-Serag; Jessica A Davila; Robert Morgan; Katherine A McGlynn Journal: Gastroenterology Date: 2005-03 Impact factor: 22.682
Authors: Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: D M Parkin; P Srivatanakul; M Khlat; D Chenvidhya; P Chotiwan; S Insiripong; K A L'Abbé; C P Wild Journal: Int J Cancer Date: 1991-05-30 Impact factor: 7.396
Authors: Tae Y Lee; Sang S Lee; Seok W Jung; Seong H Jeon; Sung-Cheol Yun; Hyoung-Chul Oh; Seunghyun Kwon; Sung K Lee; Dong W Seo; Myung-Hwan Kim; Dong J Suh Journal: Am J Gastroenterol Date: 2008-06-28 Impact factor: 10.864
Authors: Sara Gandini; Matteo Puntoni; Brandy M Heckman-Stoddard; Barbara K Dunn; Leslie Ford; Andrea DeCensi; Eva Szabo Journal: Cancer Prev Res (Phila) Date: 2014-07-01
Authors: Xiaodan Zhang; William S Harmsen; Teresa A Mettler; W Ray Kim; Rosebud O Roberts; Terry M Therneau; Lewis R Roberts; Roongruedee Chaiteerakij Journal: Hepatology Date: 2014-07-31 Impact factor: 17.425
Authors: Martin Janicko; Sylvia Drazilova; Daniel Pella; Jan Fedacko; Peter Jarcuska Journal: World J Gastroenterol Date: 2016-07-21 Impact factor: 5.742
Authors: Jonggi Choi; Hassan M Ghoz; Thoetchai Peeraphatdit; Esha Baichoo; Benyam D Addissie; William S Harmsen; Terry M Therneau; Janet E Olson; Roongruedee Chaiteerakij; Lewis R Roberts Journal: Hepatology Date: 2016-04-26 Impact factor: 17.425